Off-label prescribing:Minimizing risks and liabilities

Psychiatric Times

Volumn 26, Issue 4, 2009, Pages 12-15

  Edersheim, Judith G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67149136826     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Oates M. Facilitating informed medical treatment through production and disclosure of research into off-label uses of Pharmaceuticals. NYU Law Rev. 2005;80:1272-1308.
2. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021-1026.
3. Kramer SI, McCall WV. Off-label prescribing: 7 steps for safer, more effective treatment. Curr Psychiatry. 2006;5:15-16,21-22,26-28.
4. Fountoulakis KN, Nimatoudis I, lacovides A, Kapri-nis G. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry. 2004; 3:4.
5. Zito JM, Derivan AT, Kratochvil CJ, et al. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. ChildAdolesc Psychiatry Ment Health. 2008;2:24.
6. Dell ML, Vaughan BS, Kratochvil CJ. Ethics and the prescription pad. Child Adolesc Psychiatric Clin NAm. 2008;17:93-111, ix.
7. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediat Adolesc Med. 2003;157:17-25.
8. Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. JAmAcad Child Adolesc Psychia-try. 2002:41:514-521.
9. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007:64:466-472.
10. Dresser R. At law: the curious case of off-label use. Hastings Cent Rep. 2007;37:9-11.
11. Bright JL. Positive outcomes through the appropriate use of off-label prescribing. Arch Intern Med. 2006:166:2554-2555.
12. Psaty BM, Ray W. FDA guidance on off-label promotion and state of the literature from sponsors. JAMA. 2008:299:1949-1951.
13. Stafford RS. Regulating off-label use: rethinking the role of the FDA. NEnglJMed. 2008:358:1427-1429.
14. Beck JM, Azari ED. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J. 1998:53:71-104.
15. Frank B, Gupta S, McGlynn DJ. Psychotropic medications and informed consent: a review. Ann Clin Psy chiatry. 2008:20:87-95.
16. Krautkamer CJ. Neurontin and off-label market ing. Virtual Mentor: AMA J Ethics. 2006;8(6):397-402.
17. American Psychiatric Association. Position statement. Patient Access to Treatments Prescribed by Their Physicians. July 2007. http://www.psych.org/ MainMenu/EducationCareerDevelopment/Library/PositionStatements.aspx. Accessed December 8,2008.
18. Buckman Company vPlantiffs Legal Committee. 531 US 341,121 SCt1O12(2001).
19. Simon RI, Gold LH. Textbook of Forensic Psychiatry Arlington, VA: American Psychiatric Publishing, Inc; 2004:187-188.
20. Appelbaum PS, Gutheil TG. Clinical Handbook of Psychiatry and the Law 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2007:126-1 27.